GLP-1 use linked to lower dialysis risk in bipolar disorder with CKD

The wire

1. 01A new-user active-comparator study in adults with bipolar disorder and stage 3 or earlier CKD found GLP-1 receptor agonist use associated with lower kidney replacement therapy risk versus DPP-4 inhibitors (aHR 0.56, 95% CI 0.50-0.64).
2. 02Findings held across sex, race, obesity status and psychotropic subgroups including lithium, which matters for clinicians weighing metabolic therapy in psychiatric patients with renal disease.
3. 03Health care utilization showed no significant difference after propensity matching, and the authors call the results exploratory and retrospective, requiring prospective confirmation before causality is assumed.

From the source

GLP-1 Receptor Agonists and Risk of Kidney Replacement Therapy and Health Care Utilization in Bipolar Disorder With Chronic Kidney Disease

The Journal of clinical psychiatry · 2026 Oct 5 · Singh B, Gonzalez Suarez ML, Ali HM et al.